Abstract
Watercress is an excellent source of phenethyl isothiocyanate (PEITC), an effective inhibitor of nitrosamine carcinogenesis in rodents. The mechanism of inhibition is believed to be due in part to inhibition of cytochrome P450 (P450) enzymes. P450 2A6 is a catalyst for the metabolic activation of several nitrosamines. In this study, we investigated the effect of watercress consumption on coumarin 7-hydroxylation, a P450 2A6-specific reaction, in a group of 15 nonsmoking, healthy volunteers. The urinary excretion of 7-hydroxycoumarin (7OHC) was determined. For 6 of the 15 subjects, watercress consumption decreased the amount of 7OHC excreted in the first 2 h following coumarin administration. However, the mean 0- to 2-h excretion of 7OHC for all 15 subjects was not significantly lowered by the consumption of watercress, 2.8 ± 0.78 versus 3.1 ± 0.53 mg (±S.D.). The mean 7OHC excreted from 2 to 4 h (1.1 ± 0.50 mg) was significantly higher (P = 0.027) during watercress consumption than before (0.77 ± 0.22 mg), suggesting a delay in coumarin metabolism. Total excretion of 7OHC was unaffected by watercress consumption. Therefore, under the conditions of our study, PEITC and other constituents of watercress had at most a marginal inhibitory effect on P450 2A6-catalyzed coumarin 7-hydroxylation.
Footnotes
-
Send reprint requests to: Dr. Sharon E. Murphy, University of Minnesota Cancer Center, Box 806 Mayo, 420 Delaware St. SE, Minneapolis, MN 55455. E-mail: murph062{at}umn.edu
-
This study was supported by Grant CA-46535 from the National Cancer Institute and a grant from the University of Minnesota Cancer Center.
- Abbreviations used are::
- PEITC
- phenethyl isothiocyanate
- PEITC-NAC
- N-acetyl-S-(N-phenethylthiocarbamoyl)-l-cysteine
- NBzMA
- N-nitrosobenzylmethylamine
- NNAL
- 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol
- NNAL-Gluc
- [4-(methylnitrosamino)-1-(3-pyridyl)but-1-yl]β-O-d-glucosiduronic acid
- NNK
- 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
- 7OHC
- 7-hydroxycoumarin
- P450
- cytochrome P450
- Received April 4, 2000.
- Accepted February 7, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|